Pilot study evaluates intravitreal sirolimus safety and vision preservation in geographic atrophy
This pilot study assessed whether intravitreal sirolimus injections are safe and can help preserve vision in patients with bilateral geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Participants aged 56 years or older with GA received sirolimus injections into one eye every 2 months over 1 year, with follow-up eye exams conducted at 8 or more visits. The abstract does not report the sample size, outcomes measured, or findings.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 7, 2021 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- 12 months
- Population
- People at least 56 years of age with geographic atrophy related to age-related macular degeneration in both eyes
- Primary outcome
- Safety and vision preservation in patients with geographic atrophy
- Effect size
- —
- Significance
- Not reported
- Journal
- National Eye Institute (NEI)
- Published
- Jul 7, 2021
Sources
Primary source
- National Eye Institute (NEI) ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.